Clinical Trial Finds Azithromycin Pills Equal to Penicillin Shots for Treating Early Syphilis
In a clinical trial involving HIV-negative volunteers with early-stage syphilis, researchers have found that oral antibiotic pills (azithromycin) are as effective as penicillin injections in curing early-stage syphilis. The study was supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Edward W. Hook, III, M.D., of the University of Alabama at Birmingham, led the trial. Between June 2000 and March 2007, HIV-negative volunteers aged 18 to 55 enrolled at eight sites in the United States and Madagascar. Volunteers were randomly assigned to receive either two injections of benzathine penicillin G or four tablets of the broad-spectrum antimicrobial macrolide drug azithromycin. Of 517 total enrollees, 469 were included in an intention-to-treat analysis. Among azithromycin recipients, 77.6 percent (180 out of 232) were cured of syphilis, while cure rate among penicillin recipients was 78.5 percent (186 out of 237).
Although long-acting penicillin delivered by injection is recommended as the preferred treatment for early syphilis, the authors note that this therapy has shortcomings, particularly in resource-limited settings. Penicillin injections can cause allergic reactions, the drug must be refrigerated, and must be administrated by trained personnel. The orally administered azithromycin may provide a good alternative for treating HIV-negative people with early-stage syphilis, the scientists conclude. They note that there is a potential for syphilis-causing bacteria to acquire resistance to macrolide drugs such as azithromycin and they recommend continued research into this possibility.
Detailed information about the study’s design is available at clinicaltrials.gov at http://www.clinicaltrials.gov/ct2/show/NCT00031499?term=NCT00031499&rank=1
EW Hook et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. Journal of Infectious Diseases DOI: 10.1086/652239 (2010).
Who: NIAID Director Anthony S. Fauci, M.D., and Carolyn Deal, Ph.D., chief, Sexually Transmitted Diseases Branch, Division of Microbiology and Infectious Diseases, NIAID, are available to speak about this study.
Contact To schedule interviews, please contact Anne A. Oplinger, 301-402-1663, email@example.com.
NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
The National Institutes of Health (NIH)—The Nation’s Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
The National Institutes of Health (NIH) — The Nation’s Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.